We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sean
Knight
sean.knight@manchester.ac.uk
Sean
Knight
sean.knight@manchester.ac.uk
Malignant neoplasms of respiratory and intrathoracic organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Malignant pleural mesothelioma is often diagnosed late and invariably leads to death. There is no curative treatment and the 5 year survival rate is only 5%. The immune system is central to developing mesothelioma. Current research suggests that asbestos fibres lead to persistent inflammation that cause damage to cells on the chest wall and surface of the lung. Over time cancer driving changes occur in the DNA of these cells leading to mesothelioma. We think that proteins involved in mediating inflammation may be new targets for treatment. Dr Finegan has shown that inhibition of one inflammatory mediator, ERK5, leads to regression of mesothelioma in laboratory models. However we do not know how much ERK5 is expressed in human mesothelioma and whether inhibition of ERK5 will work in people with mesothelioma. This study will analyse expression of ERK5 in patients with mesothelioma and will set up a new model using surplus human tissue from clinical procedures to evaluate the effect of ERK5 inhibition on mesothelioma properties. If we demonstrate effectiveness of ERK5 inhibition in this study we will be in a position to plan an early clinical trial using this therapy.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
1. Lack capacity to provide informed consent 2. Concurrent infection at the time of pleural procedure 3. Known diagnosis of blood borne virus (HIV, hepatitis C and Hepatitis B) 4. Current infection with mycobacterium tuberculosis
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by June Hancock Mesothelioma Research Fund .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 59487
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
